Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1992-6-11
|
pubmed:abstractText |
The uricosuric effect of DuP-753, a novel, specific angiotensin II receptor antagonist, has been explored in a healthy male Japanese volunteers, given single oral doses of 25, 50, 100 or 200 mg (n = 6), or 100 mg (n = 6) or placebo (n = 3) once daily for 7 consecutive days. In the single-dose study, serum uric acid measured at 4 h after dosing showed a dose dependent decrease; the reductions from the corresponding pre-dose values were: 0.32 (25 mg), 0.77 (50 mg), 1.25 (100 mg) and 1.33 mg.dl-1 (200 mg). The urinary excretion of uric acid within the first 4 h after treatment was also increased in a dose-dependent manner, whereas the urinary excretion of creatinine remained unchanged. In the multiple-dose study, DuP-753 significantly decreased the serum uric acid concentration measured 4 h both after the first (pre-dose value: 5.68 vs 4 h after: 4.48 mg.dl-1) and last administrations (4.42 mg.dl-1). Simultaneously, the ratio of urinary uric acid to creatinine excretion was significantly increased within the first 4 h both after the first (DuP-753: 1.190 vs placebo: 0.576) and last administrations (1.02 vs 0.576). The findings suggest that DuP-753 possesses a uricosuric effect both after single and multiple doses in healthy subjects. The effect should be further examined in hypertensive patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Uric Acid
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0031-6970
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
333-5
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:1577054-Adult,
pubmed-meshheading:1577054-Angiotensin Receptor Antagonists,
pubmed-meshheading:1577054-Biphenyl Compounds,
pubmed-meshheading:1577054-Creatinine,
pubmed-meshheading:1577054-Dose-Response Relationship, Drug,
pubmed-meshheading:1577054-Humans,
pubmed-meshheading:1577054-Imidazoles,
pubmed-meshheading:1577054-Immunoenzyme Techniques,
pubmed-meshheading:1577054-Losartan,
pubmed-meshheading:1577054-Male,
pubmed-meshheading:1577054-Pilot Projects,
pubmed-meshheading:1577054-Reference Values,
pubmed-meshheading:1577054-Tetrazoles,
pubmed-meshheading:1577054-Uric Acid
|
pubmed:year |
1992
|
pubmed:articleTitle |
Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.
|
pubmed:affiliation |
Department of Pharmacology, Hamamatsu University School of Medicine, Japan.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|